PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines

BACKGROUND: The US Food and Drug Administration (FDA) has approved several immunotherapeutic drugs for cancer since 2010, and many more are still being evaluated in other clinical studies. These inhibitors significantly increase response rates and result in the treatment of patients with advanced ca...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Adv Res
Main Authors: Safi, Mohammed, Ahmed, Hyat, Al-Azab, Mahmoud, Xia, Yun-long, Shan, Xiu, Al-radhi, Mohammed, Al-danakh, Abdullah, Shopit, Abdullah, Liu, Jiwei
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2020
Teme:
Medicine
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020146/
https://ncbi.nlm.nih.gov/pubmed/33842004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jare.2020.09.006
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki